Bio-Path Holdings, Inc. (NASDAQ:BPTH) Sees Significant Drop in Short Interest

Bio-Path Holdings, Inc. (NASDAQ:BPTH) saw a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 30,900 shares, a decrease of 18.9% from the November 15th total of 38,100 shares. Approximately 0.7% of the shares of the stock are short sold. Based on an average daily volume of 1,160,000 shares, the short-interest ratio is presently 0.0 days.

Bio-Path Stock Up 1.3 %

NASDAQ BPTH traded up $0.01 during trading hours on Monday, reaching $0.67. The company’s stock had a trading volume of 4,598 shares, compared to its average volume of 1,054,938. The firm’s 50-day moving average price is $0.90 and its 200-day moving average price is $1.34. Bio-Path has a 1 year low of $0.59 and a 1 year high of $12.00.

Hedge Funds Weigh In On Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC acquired a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.74% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Bio-Path in a research note on Tuesday, December 10th. They issued a “sell” rating for the company.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.